Sotera Health Company Q3 2026 Earnings Call Summary
Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.
How this was made

The 30-second read
Why it matters
The earnings call provides fresh guidance on revenue, capex, and leverage, offering traders new data to adjust positions.
Market read
The disclosed guidance and demand softness are material for investors tracking healthcare services and sterilization niche.
What to watch
Potential upside from upcoming M&A activity in sterilization services not reflected in current guidance.
Background
Sotera Health provides sterilization and lab testing services through its Sterigenics, Nelson Labs, and Nordion units.
Market effects
Sterilization services sector may see broader scrutiny on demand trends in Europe.
European medical‑device market softness could affect related suppliers.
Limited to healthcare services investors; no macro‑wide impact.
Counterpoint
If capex cuts free cash flow, the stock could rally on balance‑sheet strength.
Key entities
- companySotera Health
Provider of sterilization and lab testing services.



